Gillian M. Fisher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gillian M. Fisher has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Katherine T. Andrews
Institute for Biomedicine and Glycomics Griffith University Southport Queensland Australia
12 shared publications - Tina S. Skinner-Adams
Institute for Biomedicine and Glycomics Griffith University Southport Queensland Australia
6 shared publications - Claudiu Trandafir Supuran
Department of NEUROFARBA, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, Polo Scientifico, Via U. Schiff 6, Sesto Fiorentino, Firenze, 50019, Italy
3 shared publications - Clemente Capasso
Department of Biology, Agriculture and Food Sciences, National Research Council (CNR), Institute of Biosciences and Bioresources, Via P. Castellino, 111, 80131 Naples, Italy
3 shared publications Sally-Ann Poulsen
Eskitis Institute for Drug Discovery, Griffith University, Nathan, Queensland 4111, Australia
3 shared publications- Sally-Ann Poulsen
Institute for Biomedicine and Glycomics, Griffith University, Gold Coast, Queensland 4222, Australia
3 shared publications
Latest Publications
- Open Access
Thymidine kinase-independent click chemistry DNADetect™ probes for DNA proliferation assessment in malaria parasites
Metabolic chemical probes are small molecule reagents that utilise naturally occurring biosynthetic enzymes for in situ incorporation into biomolecules of interest. These reagents can be used to label, detect, and track important biological processes within living cells including protein synthesis, protein glycosylation and nucleic acid proliferation. A limitation of current chemical probes, which have largely focused on mammalian cells, is that they often cannot be applied to other organisms due to metabolic differences. For example, the thymidine derivative 5-ethynyl-2’-deoxyuridine (EdU) is a gold standard metabolic chemical probe for assessing DNA proliferation in mammalian cells however is unsuitable for the study of malaria parasites due to Plasmodium species lacking the thymidine kinase enzyme that is essential for metabolism of EdU. Herein we report the design and synthesis of new thymidine-based probes that sidestep the requirement for a thymidine kinase enzyme in Plasmodium . Two of these DNADetect™ probes exhibit robust labelling of replicating asexual intraerythrocytic P. falciparum parasites, as determined by flow cytometry using copper catalysed azide-alkyne cycloaddition (CuAAC) to a fluorescent azide. The DNADetect™ chemical probes are synthetically accessible and thus can be made widely available to researchers as tools to further understand the biology of different Plasmodium species, including laboratory lines and clinical isolates.
Open AccessThymidine kinase-independent click chemistry DNADetect™ probes for DNA proliferation assessment in malaria parasites
Metabolic chemical probes are small molecule reagents that utilise naturally occurring biosynthetic enzymes for in situ incorporation into biomolecules of interest. These reagents can be used to label, detect, and track important biological processes within living cells including protein synthesis, protein glycosylation and nucleic acid proliferation. A limitation of current chemical probes, which have largely focused on mammalian cells, is that they often cannot be applied to other organisms due to metabolic differences. For example, the thymidine derivative 5-ethynyl-2’-deoxyuridine (EdU) is a gold standard metabolic chemical probe for assessing DNA proliferation in mammalian cells however is unsuitable for the study of malaria parasites due to Plasmodium species lacking the thymidine kinase enzyme that is essential for metabolism of EdU. Herein we report the design and synthesis of new thymidine-based probes that sidestep the requirement for a thymidine kinase enzyme in Plasmodium . Two of these DNADetect™ probes exhibit robust labelling of replicating asexual intraerythrocytic P. falciparum parasites, as determined by flow cytometry using copper catalysed azide-alkyne cycloaddition (CuAAC) to a fluorescent azide. The DNADetect™ chemical probes are synthetically accessible and thus can be made widely available to researchers as tools to further understand the biology of different Plasmodium species, including laboratory lines and clinical isolates.
- Open Access
- 23 August 2021
- Published by Elsevier in International Journal for Parasitology: Drugs and Drug Resistance
- Vol. 17, 118-127
Histone deacetylase inhibitor AR-42 and achiral analogues kill malaria parasites in vitro and in mice
- 23 August 2021
- Published by Elsevier in International Journal for Parasitology: Drugs and Drug Resistance
- Vol. 17, 118-127
Open AccessHistone deacetylase inhibitor AR-42 and achiral analogues kill malaria parasites in vitro and in mice
- Open Access
- 1 April 2017
- Published by Elsevier in International Journal for Parasitology: Drugs and Drug Resistance
- Vol. 7 (1) , 61-70
Investigating the antiplasmodial activity of primary sulfonamide compounds identified in open source malaria data
- 1 April 2017
- Published by Elsevier in International Journal for Parasitology: Drugs and Drug Resistance
- Vol. 7 (1) , 61-70
Open AccessInvestigating the antiplasmodial activity of primary sulfonamide compounds identified in open source malaria data
- 1 July 2016
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 60 (7) , 4361-4363
Adaptation of the [ 3 H]Hypoxanthine Uptake Assay for In Vitro -Cultured Plasmodium knowlesi Malaria Parasites
The zoonotic malaria parasite Plasmodium knowlesi has recently been established in continuous in vitro culture. Here, the Plasmodium falciparum [ 3 H]hypoxanthine uptake assay was adapted for P. knowlesi and used to determine the sensitivity of this parasite to chloroquine, cycloguanil, and clindamycin. The data demonstrate that P. knowlesi is sensitive to all drugs, with 50% inhibitory concentrations (IC 50 s) consistent with those obtained with P. falciparum . This assay provides a platform to use P. knowlesi in vitro for drug discovery.
- 1 July 2016
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 60 (7) , 4361-4363
Adaptation of the [ 3 H]Hypoxanthine Uptake Assay for In Vitro -Cultured Plasmodium knowlesi Malaria Parasites
The zoonotic malaria parasite Plasmodium knowlesi has recently been established in continuous in vitro culture. Here, the Plasmodium falciparum [ 3 H]hypoxanthine uptake assay was adapted for P. knowlesi and used to determine the sensitivity of this parasite to chloroquine, cycloguanil, and clindamycin. The data demonstrate that P. knowlesi is sensitive to all drugs, with 50% inhibitory concentrations (IC 50 s) consistent with those obtained with P. falciparum . This assay provides a platform to use P. knowlesi in vitro for drug discovery.
- Open Access
- 1 May 2016
- Published by Elsevier in Drug Discovery Today
- Vol. 21 (5) , 725-739
Defining the targets of antiparasitic compounds
- 1 May 2016
- Published by Elsevier in Drug Discovery Today
- Vol. 21 (5) , 725-739
Open AccessDefining the targets of antiparasitic compounds
- 1 February 2015
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 23 (3) , 526-531
Sulfonamide inhibition studies of the η-class carbonic anhydrase from the malaria pathogen Plasmodium falciparum
- 1 February 2015
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 23 (3) , 526-531
Sulfonamide inhibition studies of the η-class carbonic anhydrase from the malaria pathogen Plasmodium falciparum
- Top Cited Papers
- 1 September 2014
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 24 (18) , 4389-4396
Discovery of a new family of carbonic anhydrases in the malaria pathogen Plasmodium falciparum—The η-carbonic anhydrases
- 1 September 2014
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 24 (18) , 4389-4396
Top Cited PapersDiscovery of a new family of carbonic anhydrases in the malaria pathogen Plasmodium falciparum—The η-carbonic anhydrases
- Top Cited PapersOpen Access
- 1 August 2014
- Published by Elsevier in International Journal for Parasitology: Drugs and Drug Resistance
- Vol. 4 (2) , 95-111
Drug repurposing and human parasitic protozoan diseases
- 1 August 2014
- Published by Elsevier in International Journal for Parasitology: Drugs and Drug Resistance
- Vol. 4 (2) , 95-111
Top Cited PapersOpen AccessDrug repurposing and human parasitic protozoan diseases
- 1 July 2014
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 58 (7) , 3666-3678
Lysine Acetylation in Sexual Stage Malaria Parasites Is a Target for Antimalarial Small Molecules
Therapies to prevent transmission of malaria parasites to the mosquito vector are a vital part of the global malaria elimination agenda. Primaquine is currently the only drug with such activity; however, its use is limited by side effects. The development of transmission-blocking strategies requires an understanding of sexual stage malaria parasite (gametocyte) biology and the identification of new drug leads. Lysine acetylation is an important posttranslational modification involved in regulating eukaryotic gene expression and other essential processes. Interfering with this process with histone deacetylase (HDAC) inhibitors is a validated strategy for cancer and other diseases, including asexual stage malaria parasites. Here we confirm the expression of at least one HDAC protein in Plasmodium falciparum gametocytes and show that histone and nonhistone protein acetylation occurs in this life cycle stage. The activity of the canonical HDAC inhibitors trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA; Vorinostat) and a panel of novel HDAC inhibitors on early/late-stage gametocytes and on gamete formation was examined. Several compounds displayed early/late-stage gametocytocidal activity, with TSA being the most potent (50% inhibitory concentration, 70 to 90 nM). In contrast, no inhibitory activity was observed in P. falciparum gametocyte exflagellation experiments. Gametocytocidal HDAC inhibitors caused hyperacetylation of gametocyte histones, consistent with a mode of action targeting HDAC activity. Our data identify HDAC inhibitors as being among a limited number of compounds that target both asexual and sexual stage malaria parasites, making them a potential new starting point for gametocytocidal drug leads and valuable tools for dissecting gametocyte biology.
- 1 July 2014
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 58 (7) , 3666-3678
Lysine Acetylation in Sexual Stage Malaria Parasites Is a Target for Antimalarial Small Molecules
Therapies to prevent transmission of malaria parasites to the mosquito vector are a vital part of the global malaria elimination agenda. Primaquine is currently the only drug with such activity; however, its use is limited by side effects. The development of transmission-blocking strategies requires an understanding of sexual stage malaria parasite (gametocyte) biology and the identification of new drug leads. Lysine acetylation is an important posttranslational modification involved in regulating eukaryotic gene expression and other essential processes. Interfering with this process with histone deacetylase (HDAC) inhibitors is a validated strategy for cancer and other diseases, including asexual stage malaria parasites. Here we confirm the expression of at least one HDAC protein in Plasmodium falciparum gametocytes and show that histone and nonhistone protein acetylation occurs in this life cycle stage. The activity of the canonical HDAC inhibitors trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA; Vorinostat) and a panel of novel HDAC inhibitors on early/late-stage gametocytes and on gamete formation was examined. Several compounds displayed early/late-stage gametocytocidal activity, with TSA being the most potent (50% inhibitory concentration, 70 to 90 nM). In contrast, no inhibitory activity was observed in P. falciparum gametocyte exflagellation experiments. Gametocytocidal HDAC inhibitors caused hyperacetylation of gametocyte histones, consistent with a mode of action targeting HDAC activity. Our data identify HDAC inhibitors as being among a limited number of compounds that target both asexual and sexual stage malaria parasites, making them a potential new starting point for gametocytocidal drug leads and valuable tools for dissecting gametocyte biology.
- 3 June 2014
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 84 (4) , 462-472
Synthesis and Evaluation of Antimalarial Properties of Novel 4‐Aminoquinoline Hybrid Compounds
Pharmacophore hybridization has recently been employed in the search for antimalarial lead compounds. This approach chemically links two pharmacophores, each with their own antimalarial activity and ideally with different modes of action, into a single hybrid molecule with the goal to improve therapeutic properties. In this paper, we report the synthesis of novel 7‐chloro‐4‐aminoquinoline/primary sulfonamide hybrid compounds. The chlorinated 4‐aminoquinoline scaffold is the core structure of chloroquine, an established antimalarial drug, while the primary sulfonamide functional group has a proven track record of efficacy and safety in many clinically used drugs and was recently shown to exhibit some antimalarial activity. The activity of the hybrid compounds was determined against chloroquine‐sensitive (3D7) and chloroquine‐resistant (Dd2) Plasmodium falciparum strains. While the hybrid compounds had lower antimalarial activity when compared to chloroquine, they demonstrated a number of interesting structure–activity relationship (SAR) trends including the potential to overcome the resistance profile of chloroquine.
- 3 June 2014
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 84 (4) , 462-472
Synthesis and Evaluation of Antimalarial Properties of Novel 4‐Aminoquinoline Hybrid Compounds
Pharmacophore hybridization has recently been employed in the search for antimalarial lead compounds. This approach chemically links two pharmacophores, each with their own antimalarial activity and ideally with different modes of action, into a single hybrid molecule with the goal to improve therapeutic properties. In this paper, we report the synthesis of novel 7‐chloro‐4‐aminoquinoline/primary sulfonamide hybrid compounds. The chlorinated 4‐aminoquinoline scaffold is the core structure of chloroquine, an established antimalarial drug, while the primary sulfonamide functional group has a proven track record of efficacy and safety in many clinically used drugs and was recently shown to exhibit some antimalarial activity. The activity of the hybrid compounds was determined against chloroquine‐sensitive (3D7) and chloroquine‐resistant (Dd2) Plasmodium falciparum strains. While the hybrid compounds had lower antimalarial activity when compared to chloroquine, they demonstrated a number of interesting structure–activity relationship (SAR) trends including the potential to overcome the resistance profile of chloroquine.